PU H71 companion diagnostic - Samus Therapeutics

Drug Profile

PU H71 companion diagnostic - Samus Therapeutics

Alternative Names: 124I-PU-H71; PU H71 PET enhancer; PU H71 positron emission tomography enhancer

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Samus Therapeutics
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (IV)
  • 31 Jul 2011 Samus Therapeutics obtains a licence to the patent covering PU H71 as a companion diagnostic
  • 01 Jul 2011 Memorial Sloan-Kettering Cancer Center initiates enrolment in a phase I trial for Cancer (Diagnosis) and Diagnostic imaging in USA (NCT01393509)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top